Opportunity to Host Immunotherapy Webinars
Principles and Application in Immunotherapy of Cancer is an education series designed for multidisciplinary oncology care teams. This unique webinar series will provide a full overview of the core principles of immunotherapy and a review of issues related to the clinical application of these therapies in Melanoma and Lung Cancer. The webinars are offered at no cost to the center.
Your program is invited to participate in a 60-minute, live teleconference and webcast in one of two distinct education tracks—Melanoma and/or Lung Cancer. These tumor-specific tracks have been developed by a faculty committee composed of 1 physician expert and 1 nurse practitioner along with input from 10 additional presenting faculty. The interactive format is designed so that your team members can learn and connect directly with expert faculty well versed in immunotherapy principles and clinical application, participation will be limited to your cancer center team—all from the comfort and convenience of your cancer center.
Your participating team members will be able to:
- Describe the core principles of cancer immunotherapy as they relate to Melanoma or Lung Cancer
- Identify patients with Melanoma or Lung Cancer who are appropriate candidates for an immunotherapy approach based on the latest clinical trial data
- Manage adverse events associated with Melanoma or Lung Cancer immunotherapy treatment.
This series is jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC, in partnership with ACCC. This activity is supported by educational grants from Merck and Genentech.
Please contact Lorna Lucas to learn how your program can participate.
The Association of Community Cancer Centers and Medscape Oncology are pleased to provide an online educational initiative that offers a community provider perspective about important cancer treatment and care issues, as well as emerging data and treatment strategies presented at scientific meetings, such as those of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).